|
This complaint was reopened in reference to qab 2154.Manufacturing site evaluation: manufacturing and quality control data: the progav® was manufactured by a qualified employee in september 2009.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The progav® has a normal pressure range of 0 to 20 cmh2o.The valve was inspected as article fv479t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specification.Device examination: the valve was received submersed in an unidentified liquid in the provided returnkit.Visual inspection: a deformation of the outer housing was observed through visual inspection.A measurement of the plane parallelism was performed which confirmed the deformation.Permeability test: a permeability test has shown that the valve was permeable.Adjustment test: the progav® was tested and was adjustable throughout the normal range.Braking force and brake function test: the brake functionality test has shown that the brake function was operational, however, the braking force required was not within the given specification.Result first, a visual inspection of the progav® was performed.A deformation of the outer housing was observed, which was confirmed through a measurement of the plane parallelism.Next, the permeability, adjustability, as well as the brake functionally and brake force, of the valve were tested.The valve was permeable and was adjustable to all specified pressures.Although the brake function was operational, a reduced brake release force was observed which was likely caused by the defamation of the housing diaphragm.Finally, the valve was dismantled.A build-up of a substance (likely protein) was observed inside the valve.Based on the investigation, deposits were observed inside the valve which may have led to the reported malfunction.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hydrocephalus (hc)-therapy by shunt implants.Manufacturing defects at the time of release have been excluded.The valve met all specifications of the final inspection when released from christoph miethke (b)(4).No further regulatory actions are required.
|